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Abstract: Oral valganciclovir is a new and highly efficacious alternative to the chronic 
administration of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in HIV-infected 
patients. In addition to its excellent bioavailability and favorable pharmacokinetic profile, valgan-
ciclovir has also proved cost effective and is the most widely used drug in the armamentarium for 
the treatment of CMV retinitis. Valganciclovir is a prodrug of ganciclovir, the erstwhile commonly 
used therapy. In March 2001, the US Food and Drug Administration approved valganciclovir for 
the induction and maintenance treatment of CMV disease, including CMV retinitis. Valganciclvoir 
has compared favorably with both oral and intravenous treatments for induction and maintenance 
therapy with ganciclovir. The reduced pill burden and the ease of oral administration has helped 
avoid the risks associated with intravenous therapy. The most serious adverse event is neutropenia, 
which makes the patient susceptible to infections. In the current review, we have compiled all the 
available evidence-based information on valganciclovir.
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Introduction
Cytomegalovirus (CMV) retinitis is the leading cause of visual impairment in patients with 
human immunodeficiency virus (HIV), and typically occurs in HIV-positive individuals 
with CD4 count below 50 cells/mm3.1–3 Historically, the most utilized antiviral agent has 
been ganciclovir, which was initially licensed as an intravenous agent. In an attempt to 
make an oral preparation with convenient dosing that has the safety profile, efficacy and 
bioavailability comparable to ganciclovir, the prodrug was developed.4,5 Valganciclovir, 
the valine ester of ganciclovir, was the first systemic agent found to be as effective as 
intravenous ganciclovir, and is the oral prodrug of the popular anti-CMV drug ganciclovir. 
Valganciclovir has answered the great need of patients with CMV retinitis for an injection 
free medication in the induction and maintenance phases of therapy.5,6 In this review we 
highlight the pharmacokinetics and pharmacodynamics of valganciclovir and address the 
issues of clinical trials and related studies. We also discuss valganciclovir drug interac-
tions, drug economics and efficacy as a substitute to intravenous ganciclovir.
With the advent of highly active anti-retroviral therapy (HAART), the prevalence 
of CMV retinitis has drastically decreased by 75%–90% from a pre-HAART era 
prevalence of 30% or more in people with advanced AIDS.7 Of the patients having 
access to HAART, the prevalence is now less than 5%.8 Nevertheless, CMV retinitis 
still remains the chief vision threatening infection in HIV infected patients.9 Untreated 
retinitis typically progresses and can lead to the development of atrophic retinal holes 
and subsequent retinal detachment. Approximately 15% of patients develop retinal Clinical Ophthalmology 2010:4 112
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detachment even before the treatment is initiated.10,11 Thus 
CMV retinitis is thought to profoundly affect ocular morbid-
ity, and quality of life, unless timely treatment is instituted. 
Valganciclovir hydrochloride (Valcyte®; Hoffmann-La Roche 
Inc., Nutley, NJ, USA) is an US Food and Drug Administra-
tion (FDA)-approved antiviral medication for the treatment of 
CMV disease that has revolutionized the treatment of CMV 
retinitis. Studies WV 15376 and WV 15705 were the two 
pivotal studies that established the bioequivalence, efficacy, 
and safety of oral valganciclovir in comparison with oral and 
intravenous ganciclovir. These studies formed the basis for 
clinical use of oral valganciclovir and have played an impor-
tant role in the drug development. In this review we have 
compiled all the information on valganciclovir available from 
PubMed and results from a Google search from December 
1996 to June 2009. The information was also derived from 
clinical trials, case reports, abstracts and previous reviews. 
Additional references were obtained from the bibliographic 
data of published review articles. The valganciclovir pack-
age insert also provided useful information. The two pivotal 
studies are described in detail below.
Pharmacokinetics
Valganciclovir hydrochloride is a hydrochloride salt of the 
L-valyl ester of ganciclovir. It is a prodrug of ganciclovir. 
Upon absorption, it is extensively and rapidly hydrolyzed 
into the active forms of ganciclovir, which is a mixture of two 
diastereomers, by hepatic and gut esterases. Hence the pharma-
cokinetics of oral valganciclovir is essentially the same as that 
of intravenous ganciclovir.12 Treatment with valganciclovir/
ganciclovir typically stabilizes retinal lesions in two to four 
weeks, and frequently there is a complete response in one 
month. Ganciclovir (intravenous) treatment of CMV retinitis 
is associated with clearing of CMV viremia and CMV DNA 
from the buffy coat of the infected blood in 7–8 days.13
Protein binding of valganciclovir has not been established 
due to rapid and extensive conversion of oral valganciclovir 
to ganciclovir. Kidneys excrete valganciclovir as ganciclovir, 
both by glomerular filtration and active tubular secretion. 
Hence the plasma level of ganciclovir and thus terminal 
half-life is increased in patients with renal impairment.14 
Pharmacokinetic parameters are described in Table 1.
Bioavailability
Oral valganciclovir at the standard dose of 900 mg once a day 
produces a daily systemic exposure which is 1.7-fold greater 
than that attained with oral ganciclovir at the standard dose 
of 1000 mg three times daily. In addition, the area under 
curve at 24 hours/drug exposure (AUC24) of valganciclovir 
increased from 24% to 56% when compared from fed state 
to the fasting state.6 As a result, valganciclovir has greater 
CMV-suppressing ability than ganciclovir.15
The absolute bioavailability of oral valganciclovir 
is approximately 60%,16 which is 10 times higher than 
ganciclovir bioavailability after oral administration.17 The 
peptide-mediated active transport of valganciclovir due to 
the presence of valine moiety explains its increased bioavail-
ability.17–19 A dose of 900 mg/day of valganciclovir produces 
a daily exposure equivalent to the 5 mg/day daily intravenous 
dose of ganciclovir.6,17 Oral ganciclovir was developed as an 
initial attempt to provide a more convenient therapeutic regi-
men for ganciclovir (Cytovene®; Roche Laboratories), but 
was found to have low and variable bioavailability (6%–9%) 
compared to oral valganciclovir (60%). In clinical trials oral 
ganciclovir was found to be inferior to intravenous ganci-
clovir for the induction phase, as it reached a subtherapeutic 
serum level.20,21 It was however approved by the FDA for 
maintenance phase therapy of CMV retinitis.
Mechanism of action
Ganciclovir is the only metabolite of valganciclovir and it 
undergoes no further metabolism. Intracellular phosphoryla-
tion of ganciclovir forms ganciclovir triphosphate, which is the 
most active form. Ganciclovir triphosphate inhibits viral DNA 
synthesis by competing with deoxyguanosine. This prevents 
the incorporation of deoxyguanosine into elongating viral 
DNA, thus terminating DNA synthesis, chiefly of the group of 
herpes viruses. Ganciclovir monophosphate formed after the 
release of pyrophosphate is also incorporated into the growing 
viral DNA chain further slowing the process of replication.22
Clinical trials
Based on the equivalent pharmacokinetic profile and AUC24 
of oral valganciclovir compared to the conventional intra-
venous ganciclovir, Hoffmann-La Roche applied for FDA 
Table 1 Pharmacokinetics of valganciclovir22
Feature Valganciclovir Intravenous 
ganciclovir
Ganciclovir 
capsules
Dosage 900 mg qd  
with food
5 mg/kg  
once daily
1000 mg tid  
with food
Plasma half-life 
(hours)
4.08 2.9 4.420
AUC24 µg.h/mL 29.1 ± 9.7 26.5 ± 5.9 12–19.2
Oral  
Bioavailability (%)
604 Not applicable 624
Abbreviations: qd, once a day; tid, three times daily;   AUC, area under curve.Clinical Ophthalmology 2010:4 113
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approval in 1997.12 The initial FDA application was not 
approved based on the pharmacokinetics alone. Roche was 
asked to complete another randomized controlled trial dem-
onstrating the equivalence between the two drugs for the 
induction therapy of CMV retinitis.5
Study wv 15376
Unlike a traditional head-to-head study, this pivotal trial, 
Study WV 15376,5,22 was a noninferiority study designed 
to prove that oral valganciclovir was not 10% worse than 
intravenous ganciclovir. The study enrolled 160 patients 
with newly diagnosed CMV retinitis; 80 of them received 
induction therapy with intravenous ganciclovir 5 mg/kg 
for three weeks and the remaining 80 received induction 
therapy with oral valganciclovir 900 mg twice daily for three 
weeks. The patients were followed with the same therapy 
once daily for one week. All patients were then placed on 
maintenance treatment with oral valganciclovir 900 mg once 
daily. Retinal photographs were obtained at baseline visit 
and then week two and week four and evaluated by masked 
reviewers. Although most patients had zone-3 retinitis, 24% 
in each arm had zone-1 retinitis. The mean CD4 cell count 
at baseline was 54 cells/mm3 in the intravenous ganciclovir 
arm, and 58 cells/mm3 in the oral valganciclovir arm. The 
median HIV RNA at baseline was 4.9 log10 copies/mL in 
the intravenous ganciclovir arm, and 4.8 log10 copies/mL 
in the oral valganciclovir arm. This registrational study is 
summarized in Table 2.
The primary efficacy end point of the study was the pro-
gression of retinitis during the first four weeks of the therapy. 
Analysis of the primary endpoint revealed that seven patients 
(10%) in each treatment arm had progression of retinitis 
after four weeks as determined by the masked reviewer. The 
secondary efficacy end point was the time to CMV retinitis 
progression. This was not significantly different between the 
two groups (219 days in the ganciclovir arm and 226 days 
in the valganciclovir arm). Of importance, the mean time to 
progression of CMV retinitis in this trial conducted during the 
HAART era was substantially longer than the times observed 
in studies before the introduction of HAART (approximately 
70 days). No significant difference in serious adverse events 
between the two drugs was noted in the study except for the 
increased catheter related infectious complications in intra-
venous ganciclovir group.23
Study wv 15705
Study WV 1570524 enrolled 212 patients who received 
maintenance treatment with oral valganciclovir for CMV 
retinitis. Patients who were receiving intravenous ganciclovir 
for maintenance treatment of CMV retinitis were eligible 
for enrollment. The results of the study established the 
safety profile of oral valganciclovir in AIDS patients with 
Table 2 Summary of the valganciclovir registrational study wv 1537622
Total number of patients enrolled 
and randomized to either arms
160
Number of patients  
completing the study
146
induction therapy Oral valganciclovir arm: 900 mg bid for three weeks followed by 900 mg once daily for one week.
intravenous ganciclovir arm: 5 mg/kg bid for three weeks followed by 5 mg/kg once daily for one week.
Maintenance therapy All patients were given the maintenance therapy of valganciclovir of 900 mg once daily.
Primary endpoint  of the study Progression of CMv retinitis within four weeks of initiation of treatment determined as growth of lesion 750 
µm or a new retinitis lesion measuring 750 µm in diameter.
Secondary endpoint  
of the study
Secondary outcome measures included the achievement of a satisfactory response to induction treatment during 
the first four weeks, as determined by analysis of retinal photographs.    A satisfactory response was achieved when 
all of the following criteria were met: no movement of a lesion border by 1500 µm or more and no development 
of a new lesion 1500 µm or more in diameter between base line and week 4, no movement of a lesion border by 
750 µm or more and no development of a new lesion 750 µm or more in diameter between week 2 and week 4, 
no increase in retinitis activity between week 2 and week 4, and a decrease in retinitis activity between base line 
and week 4 by at least two steps on the six-step activity scale.
Bioavailability of valganciclovir 60%, about 10-fold higher than the oral ganciclovir.
Outcomes of the study 10% of patients in each arm showed progression of retinitis after four weeks. 77% of patients in the intravenous 
ganciclovir arm and 72% of patients in the oral valganciclovir showed no progression.
Adverse events Seven patients suffered retinal detachment during the first four weeks of the study.5 Twenty percent of participants 
experienced grade 3–4 adverse events by week 4.
Abbreviation: bid, twice a day.Clinical Ophthalmology 2010:4 114
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CMV retinitis. Due to the low number of clinical events it 
was not possible to calculate the mean time to CMV retinitis 
progression. The mean treatment duration was 779 days. 
No significant difference in adverse reactions particularly 
hematological abnormalities were noted between the two 
treatment arms as seen in Table 3.24
More than 30% of patients had diarrhea, nausea, and 
fever.4–6 More than 20% of patients experienced candidia-
sis, headache, dermatitis, neutropenia, anemia, insomnia, 
cough, vomiting and fatigue. 19% experienced progres-
sion of CMV retinitis during the study. Patients with CMV 
retinitis progression needed multiple cycles of induction and 
maintenance therapy. Of the 113 patients who entered the 
study with unilateral retinitis, 10 (8.8%) developed CMV 
retinitis in the previously unaffected eye. Adverse reactions 
are summarized in Table 3.
Administration and dosage
Valganciclovir is available as 496.3 mg film-coated tablets 
of valganciclovir hydrochloride corresponding to 450 mg of 
valganciclovir. It is stored between 15–30 °C. Valganciclovir 
administration with food maximizes its bioavailability. Fatty 
foods significantly increase the bioavailability. The tablets 
are not to be broken or crushed because of its potential tera-
togenic and carcinogenic property in humans. Valganciclovir 
tablet is not a one-to-one substitute for ganciclovir capsules. 
As the bioavailability of oral valganciclovir is significantly 
higher than the ganciclovir capsules, patients turning from 
ganciclovir capsules to oral valganciclovir should be warned 
of possible over dosage if they take more than the prescribed 
valganciclovir.22 The treatment regimen is summarized in 
Table 4.
Patients on oral valganciclovir therapy must undergo com-
plete ophthalmic evaluations periodically. This serves as the 
basis to judge the recovery of retinitis with treatment. Com-
plete blood count with total and differential counts, serum 
creatinine levels 2–3 times a week during the induction phase, 
and once a week during maintenance therapy is recommended 
to identify any hematological adverse events.22
Treatment of CMV retinitis with oral valganciclovir is 
suppressive but not curative.8 Valganciclovir profoundly 
suppresses viral replication, but does not eradicate the virus 
itself. Cessation of oral Valganciclovir therapy in a pro-
foundly immunosuppressed person results in reactivation 
of CMV viral replication. Therefore maintenance therapy is 
essential in the successful management of CMV retinitis if 
the patient’s immune function remains poor. Recent reports 
from the US Public Health Service (USPHS) advises discon-
tinuation of maintenance oral valganciclovir in a patient on 
HAART therapy with quiescent CMV retinitis having CD4 
count persistently greater than 100–150 cells/mm3 for at least 
six months, backed by cautious clinical, immunological and 
ophthalmological monitoring.25,26 Maintenance therapy is 
reconsidered if the CD4 count falls below 100–150 cells/mm3 
or the patient develops other signs of HIV progression.27
On September 12, 2003, valganciclovir was also approved 
for the prevention of CMV disease in kidney,28 heart, lung,29 
liver,17 and pancreas transplant recipients.16 This was based 
on the results of the clinical trial, PV 16000, in which oral 
valganciclovir decreased the incidence of CMV disease, 
including CMV syndrome and tissue-invasive disease in 
the first six months after transplantation.22 Valganciclovir 
is currently being investigated for its efficacy in prevention 
and treatment of CMV end-organ disease in HIV infected 
patients, congenital and neonatal CMV disease and in pre-
venting CMV disease in stem cell transplant recipients.
Alternative therapies
Approved alternative therapies for the treatment of CMV reti-
nitis in addition to intravenous ganciclovir and oral ganciclo-
vir include the ganciclovir intravitreal implant, intravenous 
foscarnet (Foscavir®; AstraZeneca, Wilmington, DE, USA) 
and intravenous cidofovir (Vistide®; Gilead, Foster City, 
CA, USA).22 For CMV retinitis, resistant to ganciclovir, the 
commonly used alternative drugs are foscarnet and cidofovir. 
With the exception of the study comparing oral valganciclovir 
to intravenous ganciclovir, there exists no head-to-head study 
between valganciclovir and any other drugs used in patients 
with CMV . Foscarnet and cidofovir act by directly inhibiting 
CMV DNA polymerases. They are considered second-line 
Table 3 Adverse reactions (%) noted in study wv 1570522
Adverse reaction Valganciclovir Intravenous   
ganciclovir
Diarrhea 16 10
Nausea 8 14
Anemia 8 8
Neutropenia (Neutrophil  
count 1000/mm3)
11 13
Headache 9 5
Cathether-related  
infections
3 11
Table 4 Treatment regimen
induction therapy 900 mg (two 450 mg tablets) bid with food for 21 days.
Maintenance therapy 900 mg (two 450 mg tablets) qd with food.
Abbreviations: qd, once a day; bid, twice a day.Clinical Ophthalmology 2010:4 115
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drugs in the management of CMV retinitis because of their 
associated adverse effects discussed in Table 5.
Gancicloivir implant
Intraocular sustained-release ganciclovir implants (Vitrasert®; 
Chiron Vision, Irvine, CA, USA) with a release rate of 
1 µg/hour of ganciclovir and intravitreal injections of ganci-
clovir have been very effective in treating CMV retinitis.5,30,31 
In the pivotal trial, patients treated with the ganciclovir 
implant had a mean time to CMV retinitis reactivation of 
220 days compared to 70 days for patients treated with intra-
venous gancicloivir.30 The risk of CMV retinitis becoming 
bilateral was 50% at six months with the sustained-release 
implant alone. However biopsy confirmed the development 
of visceral CMV disease in 31% of patients indicating lack of 
protection from systemic CMV disease with the intraocular 
implant alone. Given that CMV retinitis is the ocular manifes-
tation of a systemic infection, local therapy by itself must be 
given with awareness of systemic risks. In general, when local 
intraocular therapy is administered, it is done so in combina-
tion with systemic therapy typically oral valganciclovir.
intravenous foscarnet
A direct comparison of ganciclovir and foscarnet was con-
ducted in an open-label, randomized, multicenter clinical 
trial sponsored by Studies of Ocular Complications of AIDS 
Research Group (SOCA) in patients with AIDS and CMV . 
In the ganciclovir group, induction therapy with intravenous 
ganciclovir sodium at 5 mg/kg twice a day for two weeks 
was followed by maintenance therapy of 5 mg/kg per day. 
In the foscarnet group, induction therapy with intravenous 
foscarnet sodium at 90 mg/kg twice a day for two weeks 
was followed by maintenance therapy of 120 mg/kg per day. 
Retinitis progression, visual acuity, visual fields, mortality 
and morbidity were the outcome parameters. The mortality 
rate was significantly different between the two groups. 
Median survival times were 8.5 months for the ganciclovir 
group and 12.6 months for the foscarnet group. The median 
times to retinitis progression were similar between groups 
(53 days for foscarnet and 47 days for ganciclovir), and no 
significant difference was detected in visual acuity outcomes 
and visual field loss (29° per month for foscarnet and 31° 
per month for ganciclovir), and retinal area involvement on 
fundus photographs.32
intravenous cidofovir
The SOCA sponsored HPMPC (cidofovir) Peripheral 
Cytomegalovirus Retinitis Trial suggested the effectiveness 
of both high-dose and low-dose cidofovir in controlling CMV 
retinitis when given as intravenous infusions intermittently. 
This was a multicenter, randomized, and controlled trial 
evaluating the role of intravenous cidofovir as a treatment 
for CMV retinitis. Sixty-four AIDS patients with small, 
peripheral, untreated CMV retinitis were enrolled for the 
study. These patients were assigned to one of three groups as 
described here: the deferral group, in which cidofovir treat-
ment was withheld until CMV retinitis was found progressive; 
the low-dose cidofovir group received cidofovir, 5 mg/kg of 
body weight once a week for two weeks, then maintenance 
therapy with cidofovir, 3 mg/kg of body weight once every 
two weeks; or the third treatment group of high-dose cidofo-
vir receiving 5 mg/kg of cidofovir once a week for two weeks 
followed by maintenance therapy of cidofovir, 5 mg/kg once 
every two weeks. Concomitant administration of cidofovir 
with probenecid, adequate hydration, intermittent dosing and 
monitoring for proteinuria was found to minimize associated 
nephrotoxicity of cidofovir. In the low-dose cidofovir group, 
the median time to retinitis progression was 64 days and it 
Table 5 Alternative therapies for CMv disease15
Parameter  Ganciclovir9 Valganciclovir22 Cidofovir Foscarnet44
induction therapy iv 5 mg/kg for two weeks 900 mg bid  
for three weeks
5 mg/kg weekly  
for two weeks
iv 60 mg/kg tid  
for two weeks
Maintenance therapy iv 5 mg/kg qd 900 mg qd iv 5 mg/kg every  
two weeks
iv 30 mg/kg tid
Advantages Systemic therapy, oral  
therapy, long acting  
implants available
Systemic therapy,  
oral therapy,  
low pill burden,  
convenient dosing
Systemic therapy,  
least expensive,  
suppresses  
exacerbations
Systemic therapy
Adverse effects Myelosuppressant, large pill burden, 
intravenous regimen and infusion 
related problems, if orally- poor 
bioavailability
Myelosuppressant Nephrotoxic,  
Co-administration  
with probenicid
Nephrotoxic, electrolyte 
imbalance, intravenous  
regimen and infusion- 
related problems
Abbreviations: iv, intravenous; qd, once a day; bid, twice a day; tid, three times a day.Clinical Ophthalmology 2010:4 116
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was 21 days in the deferral group. In the high-dose group, 
the median time to progression was not reached at all. In 
conclusion, both high- and low-dose intravenous cidofovir 
delayed the progression of CMV retinitis effectively.33
Combination therapy of intravenous 
ganciclovir and foscarnet
In the SOCA-CMV Retinitis Retreatment Trial, for the 
relapsed retinitis, the combination of intravenous ganciclovir 
and foscarnet was found to be more effective than either 
drug alone. Combination of ganciclovir sodium at 5 mg/kg 
per day and foscarnet sodium at 90 mg/kg per day was 
the treatment regimen in the study. Combination therapy 
was found to be the most effective regimen in controlling 
retinitis progression, as evaluated by the centralized Fundus 
Photograph Reading Center in a masked fashion. The median 
times to retinitis progression were 1.3 months, 2.0 months, 
and 4.3 months in the foscarnet group, ganciclovir group, 
and combination therapy group, respectively. Quality-of-life 
parameters were found to be best with the combination 
therapy compared to the monotherapy groups of ganciclovir 
and foscarnet.33 However, infusion times and systemic side 
effects are significant, and in the HAART era, this treatment 
approach is rarely utilized.
Combination of ganciclovir implant 
and oral ganciclovir with intravenous 
cidofovir
In vitro data suggest that combination therapies are syner-
gistic in inhibiting viral replication. Therefore, the combina-
tion of daily oral ganciclovir and intermittent intravenous 
cidofovir was thought to be an attractive therapy for relapsed 
disease as both these act in synergy to control the systemic 
and ocular CMV disease.
The Ganciclovir-Cidofovir CMV Retinitis Trial 
(GCCRT) was a randomized, multicenter clinical trial aimed 
at comparing the regimen of the ganciclovir implant plus 
oral ganciclovir to one of intravenous cidofovir for the treat-
ment of CMV retinitis. Sixty-one patients with AIDS and 
CMV retinitis were randomized either to the regimen of the 
ganciclovir implant plus oral ganciclovir, 1 gm three times 
daily, or intravenous cidofovir, 5 mg/kg once a week for two 
weeks, followed by 5 mg/kg every other week. The results 
were as follows: Ocular outcomes were similar between 
the two groups, with retinitis progression occurring at a 
rate of 0.67 per person-year in the ganciclovir group, 0.71 
per person-year in the cidofovir group, and a 15-letter loss 
of visual acuity occurring at a rate of 0.78 per person-year 
in the ganciclovir group and 0.47 per person-year in the 
cidofovir group. Vitreous hemorrhage associated with the 
surgical procedure of placing the implant was noted in 
the ganciclovir implant group (0.13 per person-year) with 
no cases in the cidofovir group. Conversely, uveitis occurred 
more frequently in the cidofovir group (0.35 per person-
year) than in the ganciclovir group (0.09 per person-year). 
Mortality rates were not different between groups (0.41 per 
person-year for ganciclovir and 0.49 per person-year for 
cidofovir). Nephrotoxicity, the main systemic side effect of 
cidofovir was significantly more common in the cidofovir 
group (0.48 per person-year) compared to the ganciclovir 
group (0.18 per person-year).34
Advantages of systemic therapy 
with valganciclovir
1.  Systemic treatment with oral ganciclovir reduced the 
incidence of systemic CMV disease.35 The effectiveness 
of systemic ganciclovir is emphasized by the fact that 
there is an increase of 22%–35% in the incidence of new 
CMV retinitis in the untreated contralateral eye with 
intraocular treatment alone.36
2.  The convenient administration of valganciclovir has 
resulted in better patient compliance as suggested in a 
study by Claxton.37
3.  In a study with oral ganciclovir, it has been found to 
prevent CMV disease in patients with HIV infection 
and CD4 count of lesser than 100 cells/mm3. Hence, oral 
valganciclovir/ganciclovir holds promise in preventing 
CMV disease in patients with HIV infection.38
4.  Systemic treatment reduces mortality.13
Resistance to valganciclovir
Viral resistance to ganciclovir has been noted with prolonged 
treatment in patients with CMV retinitis and was first reported 
in 1989. Ganciclovir resistance has been attributed to the 
mutations in protein kinase gene UL97 and polymerase gene 
UL54.22 The incidence of ganciclovir resistance in valgan-
ciclovir therapy is similar to that in intravenous ganciclovir 
therapy. Patients showing poor clinical response but with 
persistent viral excretion are considered to have developed 
resistance to ganciclovir. In a study involving 72 immuno-
compromised patients with HIV and CMV retinitis, 20% of 
patients who failed to respond to valganciclovir were found 
to have nine different resistant strains of CMV .39 All these 
patients failed to phosphorylate ganciclovir. Surprisingly in 
some patients, valganciclovir resistance was noticed without 
any prior exposure to ganciclovir. In another study, genotypic Clinical Ophthalmology 2010:4 117
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resistance to ganciclovir was found in 9.4% of patients after 
182 days of therapy.40
Mutation in viral protein  
kinase gene UL97
Deletion of four amino acids in a highly conserved region 
of viral protein kinase results in a mutation of UL97, viral 
protein kinase gene. These viral mutants fail to phosphorylate 
ganciclovir efficiently and this is the main cause for CMV 
resistance to ganciclovir.22
Mutation in viral polymerase gene UL54
Mutation in viral polymerase gene UL54 has resulted in 
cross-resistance with other antiviral drugs acting on viral 
DNA polymerase such as cidofovir and foscarnet.22 This 
leads to reduced incorporation of the drug into the CMV 
DNA strand.
Drug interactions
No drug–drug in vivo interaction has been studied with 
valganciclovir. Valganciclovir is rapidly and extensively 
converted to ganciclovir and hence the same drug interactions 
with ganciclovir are seen with valganciclovir.22 The important 
drug interactions are discussed in Table 6.
Adverse effects
General
The common adverse events reported during maintenance 
therapy are diarrhea, nausea, vomiting, abdominal pain, 
fever, headache, insomnia, tremors, peripheral neuropathy, 
seizures, confusion, paresthesia, hallucinations, graft rejec-
tion, constipation, back pain, high blood pressure and retinal 
detachment.22,23
Myelosuppressant
Less than 5% patients had serious adverse reactions such as 
pancytopenia and aplastic anemia.22,41
Teratogenic
Valganciclovir is a FDA pregnancy category-C drug with 
reproductive toxicity similar to ganciclovir. Common terato-
genic abnormalities reported in animal models include cleft 
palate, hydrocephaly, microphthalmos and brachygnathia. 
Adequate contraception is advised to women of reproductive 
potential on valganciclovir.22
Carcinogenic
Although there is no human study to prove the carcinogenesis 
of valganciclovir, patients are warned to consider it a poten-
tial carcinogenic.
Anti-fertility
It causes azoospermia in animals due to direct cessation 
of spermatogenesis, without affecting testicular endocrine 
functioning. Suppressed fertility is reported in females in a 
different animal study.22
Special precautions
Pediatric and geriatric population
The effects of valganciclovir on pediatric and geriatric 
population have not been studied. Caution is to be exercised 
while using valganciclovir in the elderly keeping in mind the 
increased frequency of impaired renal, hepatic and cardiac 
function in them.
Nursing mothers
It is not known whether ganciclovir is secreted in human 
milk. Nursing mothers are instructed not to breast-feed if 
Table 6 valganciclovir drug interactions22
Valganciclovir interactions with Drug interactions Comments
Zidovudine Myelosuppression This calls for reduction in valganciclovir dosage 
or substitution with a different antiretroviral drug.
Didanosine Paradoxical decline in the CD4  
cell counts, despite persistent  
suppression of viral load
The probable explanation is the inhibition of 
purine nucleoside phosphorylase by ganciclovir 
and its prodrug valganciclovir.
Mycophenolate mofetil22 Myelosuppression Granulocytopenia reversed with  
granulocyte-colony stimulating factor
Probenecid22 reduces renal clearance and  
increases plasma concentration
Close monitoring advised
imipenem/cilastatin induces convulsions No human studies done
Stavudine/zalcitabine/trimethoprim22 No untoward effects reported
Nephrotoxic drugs such as aminoglycosides,  
cisplatin, tacrolimus and amphotericin B12
increased nephrotoxicity Avoidance or cautious administration is advisedClinical Ophthalmology 2010:4 118
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they are on valganciclovir. The Centers for Disease Control 
also recommend HIV-infected mothers not to breast feed 
their infants to avoid postnatal transmission of HIV .
Contraindications
Valganciclovir is contraindicated in patients with ganci-
clovir hypersensitivity. It is contraindicated in patients 
with absolute neutrophil count less than 500/mm3, platelet 
count less than 25,000/mm3 or the hemoglobin less than 
8 g/dL.22,42
Valganciclovir is not advised in patients on hemodialysis 
or in those with creatinine clearance below 10 ml/minute, 
as the optimal daily dosage is less than 450 mg. There is 
no study regarding the effects of peritoneal dialysis on the 
excretion of valganciclovir.14
Drug economics
Oral valganciclovir is an efficient and advantageous sub-
stitute for ganciclovir in many ways. It is an effective 
alternative to intravenous ganciclovir43 in induction and 
maintenance therapy of CMV retinitis in HIV patients, 
and is found to achieve significantly higher systemic levels 
than oral ganciclovir. Based on the wholesale prices in the 
United States, a two-week induction therapy with intrave-
nous ganciclovir costs US$1,583, while oral valganciclovir 
costs US$2,136. For maintenance treatment, intravenous 
ganciclovir costs US$57 each day, and oral valganciclovir 
costs US$76 each day.
Valganciclovir is cost and time effective as it eliminates 
the expenses involved in hospitalization, intravenous, or 
indwelling catheterizations and nursing care associated with 
the use of parenteral ganciclovir, foscarnet or cidofovir.15,38,44 
Long-term intravenous therapy predisposes the patient to 
the risk of catheter-related complications such as thrombo-
phlebitis, intravenous line infection and sepsis.45 Although 
valganciclovir is more expensive per pill than ganciclovir, the 
costs are comparable with intravenous ganciclovir taking 
into account the cost of parenteral administration.42 Valganci-
clovir has overcome the large pill burden of oral ganciclovir 
and has improved treatment adherence. Roche has agreed to 
offer valganciclovir at a price of US$1800 for two weeks in 
developing countries of Africa and Asia, after negotiations 
with Médecins Sans Frontières’s (MSF) Access to Essential 
Medicines Campaign.11
Conclusions
Valganciclovir is a relatively safe, highly bioavailable oral 
form of ganciclovir that has greatly enhanced the efficacy 
of preventive and maintenance treatment regimens for CMV 
retinitis in AIDS patients. Valganciclovir is the only drug 
with bioavailability equivalent to the intravenous ganci-
clovir and is indicated for the treatment of serious vision 
and life-threatening CMV infections.5 Valganciclovir in 
AIDS patients has been shown to be highly effective for 
the induction and maintenance of CMV disease, and has 
significantly improved quality of life for patients with this 
disease as it has eliminated the need for chronic indwelling 
catheterization and chronic intravenous therapy for people 
with CMV retinitis.
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